• Ionis Pharmaceuticals Inc IONS.OQ reported a quarterly adjusted loss of 93 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -98 cents. The mean expectation of twenty two analysts for the quarter was for a loss of $1.12 per share. Wall Street expected results to range from $-1.43 to -81 cents per share.

• Revenue rose 10.9% to $132.00 million from a year ago; analysts expected $125.32 million.

• Ionis Pharmaceuticals Inc's reported EPS for the quarter was a loss of 93 cents​.

• The company reported a quarterly loss of $147 million.

• Ionis Pharmaceuticals Inc shares had fallen by 1.2% this quarter and lost 14.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, four analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 8 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $60.00

This summary was machine generated from LSEG data April 30 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)